GlassScriptPhysician profile
Kyle A Herald
NPI 1710238266
$64,721.80
in general payments reported to CMS, 2019-2025
36 companies · $24K in 2025
The $24K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $993 · 2022: $1,647 · 2023: $15K · 2024: $23K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $51K · Food and Beverage: $7,945 · Travel and Lodging: $2,741 · Education: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,690.00 |
| Food and Beverage | $7,944.76 |
| Travel and Lodging | $2,740.70 |
| Education | $706.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $47,715.42 | 2021-2025 | Tremfya |
| Abbvie INC. | $10,774.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,198.86 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $683.67 | 2022-2025 | Sotyktu |
| Ucb, INC. | $575.75 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $476.01 | 2021-2024 | Blu-U, Odomzo, Ilumya |
| Galderma Laboratories, L.P. | $433.73 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Genzyme Corporation | $313.35 | 2023-2025 | |
| Lilly USA, LLC | $292.85 | 2021-2024 | Olumiant, Taltz |
| Pfizer INC. | $292.36 | 2021-2025 | |
| Leo Pharma INC. | $279.55 | 2021-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $273.22 | 2021-2025 | |
| Amgen INC. | $229.34 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $227.27 | 2023-2025 | Zoryve |
| Mallinckrodt Hospital Products INC. | $134.23 | 2021-2025 | Acthar |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.16 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $93.01 | 2023-2024 | Vtama |
| Incyte Corporation | $76.02 | 2021-2024 | Opzelura |
| Chiesi USA, INC. | $67.88 | 2025 | Filsuvez |
| Organon LLC | $60.20 | 2023-2025 | Vtama, Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.53 | 2021-2022 | |
| Mylan Institutional INC. | $45.02 | 2023 | Hulio |
| Lnhc, INC | $36.89 | 2025 | Zelsuvmi |
| Genentech USA, INC. | $33.31 | 2022-2024 | Erivedge |
| Avita Medical Americas, LLC | $27.61 | 2024 | |
| Cipher Pharmaceuticals US LLC | $27.54 | 2025 | Spinosad, Natroba |
| Mayne Pharma Commercial LLC | $24.89 | 2023 | |
| Biofrontera INC. | $24.59 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $24.57 | 2023 | Evusheld |
| Krystal Biotech INC | $24.48 | 2025 | Vyjuvek |
| Alnylam Pharmaceuticals INC. | $22.35 | 2024 | Givlaari |
| Epi Health, LLC | $18.58 | 2021 | |
| Botanix Sb INC | $17.83 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $15.63 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.24 | 2024 | Ycanth |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Herald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.